PUBLISHER: DelveInsight | PRODUCT CODE: 1047132
PUBLISHER: DelveInsight | PRODUCT CODE: 1047132
DelveInsight's, "Trastuzumab- Biosimilar 2022," report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Trastuzumab Understanding
Trastuzumab: Overview
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.
Trastuzumab Biosimilars: Drugs Chapters
This segment of the Trastuzumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Trastuzumab Biosimilars: Marketed Drugs
Kanjinti is a biosimilar to trastuzumab, a recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody. The active ingredient of KANJINTI is a humanized monoclonal antibody that has the same amino acid sequence, structure and function as trastuzumab. Kanjinti has the same pharmaceutical dosage form and same strength after reconstitution as trastuzumab.
Herzuma is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer. Herzuma is the second FDA-approved trastuzumab biosimilar, following Mylan and Biocon's approval for Ogivri in December 2017 (Ogivri has not yet launched in the United States). Herzuma has also earned approval in the European Union (where it is marketed by Mundipharma), in Japan (where it is marketed by Daiichi Sankyo), and in Australia.
Further product details are provided in the report……..
Trastuzumab Biosimilars: Emerging Drugs
EG12014 is a biosimilar of trastuzumab, which is Roche's monoclonal antibody with brand name called Herceptin. A biosimilar drug is a near-identical copy of an original biologics and a different company can manufacture it after the expiration of the original biologics' patent. Eirgenix has begun preparations for a phase III clinical trial which would be conducted in the US and European nations. The outcome paves the way for new opportunities for lower-priced biosimilar drugs as patents on mainstream oncology drugs approach their expiration dates in the next few years.
HD201 is a mAb biosimilar to Roche's Herceptin which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Prestige's HD201 is in phase-III clinical development for filing with European Medicines Agency (EMA) and United States Food and Drug Administration (USFDA) in 2019.
Further product details are provided in the report……..
Trastuzumab: Therapeutic Assessment
This segment of the report provides insights about the different Trastuzumab biosimilars segregated based on following parameters that define the scope of the report, such as:
There are approx. 35+ key companies which are developing the therapies for Trastuzumab.
DelveInsight's report covers around 35+ products under different phases of clinical development like
Trastuzumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Trastuzumab: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Trastuzumab biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Trastuzumab biosimilar drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products